Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

2.700 +0.140 (+5.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 Next >
Taysha Gene Therapies Receives Orphan Drug Designation for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency From the European Commission
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
From Taysha Gene Therapies
Via Business Wire
Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 16
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Participate in Upcoming August Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Host Manufacturing Day
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Participate in Upcoming July Investor Healthcare Conference
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces Publication of Natural History Data for TSHA-120 in Giant Axonal Neuropathy in the Journal, Brain
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Host Virtual R&D Day
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Host First Annual Stockholder Meeting
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Participate in Upcoming June Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Joins the Rare Disease Company Coalition
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Expands Leadership Team with the Appointment of Chief Development Officer
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-Reviewed Journal
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces New Data on Multiple Preclinical Programs and Upcoming R&D Day
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease
From Taysha Gene Therapies, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.